Wechselwirkungen von Kaliumchlorid

Potassium chloride is contraindicated in patients on triamterene and amiloride. (Fachinformation zu Kaliumchlorid, Gegenanzeigen)

…with: • type 2 diabetes with microalbuminuria, • serum creatinine > 2.0 mg/dL in males or >1.8 mg/dL in females, • creatinine clearance < 50 mL/min, or • concomitant administration of potassium supplements or potassium-sparing diuretics (e.g., amiloride, spironolactone, or triamterene) [see Warnings and Precautions (5.1) , Adverse Reactions (6.2) , Drug Interactions… (Fachinformation zu Eplerenon, Gegenanzeigen)

• GI Toxicity with Solid Oral Dosage Forms of Potassium Chloride : Concomitant use is not recommended. (Fachinformation zu Glycopyrroniumbromid, Arzneimittelwechselwirkungen)

Solid dosage forms of potassium chlorides have produced stenotic and/or ulcerative lesions of the small bowel and deaths. (Fachinformation zu Kaliumcitrat, Warnhinweise und Vorsichtsmaßnahmen)

Information for patients Patients who receive spironolactone and hydrochlorothiazide tablets should be advised to avoid potassium supplements and foods containing high levels of potassium including salt substitutes. (Fachinformation zu Spironolacton und Hydrochlorothiazid, Vorsichtsmaßnahmen)

Potassium chloride is contraindicated in patients on triamterene and amiloride. (Fachinformation zu Kaliumchlorid, Gegenanzeigen)

Potassium chloride is contraindicated in patients on triamterene and amiloride. (Fachinformation zu Kaliumchlorid, Gegenanzeigen)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes, combination use with ARBs or ACEIs [see Contraindications ( 4 ), Warnings and Precautions ( 5.2 ), and Clinical Studies ( 14.3 )] , NSAIDs, or potassium supplements or potassium sparing diuretics. (Fachinformation zu Aliskiren, Warnhinweise und Vorsichtsmaßnahmen)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes. (Fachinformation zu Amlodipin und Benazepril, Warnhinweise und Vorsichtsmaßnahmen)

…Serum Potassium: Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart… (Fachinformation zu Amlodipin und Valsartan, Arzneimittelwechselwirkungen)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes [see Drug Interactions (7.1) ] . (Fachinformation zu Benazepril, Warnhinweise und Vorsichtsmaßnahmen)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Agents Increasing Serum Potassium Co-administration of candesartan cilexetil with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. (Fachinformation zu Candesartan, Arzneimittelwechselwirkungen)

Co-administration of candesartan cilexetil and hydrochlorothiazide tablets with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. (Fachinformation zu Candesartan und Hydrochlorothiazid, Arzneimittelwechselwirkungen)

Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium. (Fachinformation zu Captopril, Arzneimittelwechselwirkungen)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Caution is also required when cyclosporine is coadministered with potassium sparing drugs (e.g., angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists), potassium-containing drugs as well as in patients on a potassium rich diet. (Fachinformation zu Ciclosporin, Arzneimittelwechselwirkungen)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes [see Drug Interactions ( 7.3 )]. (Fachinformation zu Enalapril, Warnhinweise und Vorsichtsmaßnahmen)

Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. (Fachinformation zu Enalapril und Hydrochlorothiazid, Arzneimittelwechselwirkungen)

Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. (Fachinformation zu Enalaprilat, Arzneimittelwechselwirkungen)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Monitor serum potassium levels; use potassium supplements if necessary. (Fachinformation zu Fludrocortison, Arzneimittelwechselwirkungen)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia. (Fachinformation zu Fosinopril, Arzneimittelwechselwirkungen)

Drug Interactions Potassium supplements and potassium-sparing diuretics As noted above (“Derangements of Serum Electrolytes”), the net effect of fosinopril sodium and hydrochlorothiazide may be to elevate a patient’s serum potassium, to reduce it, or to leave it unchanged. (Fachinformation zu Fosinopril und Hydrochlorothiazid, Arzneimittelwechselwirkungen)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Coadministration of AVALIDE with potassium-sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia, sometimes severe. (Fachinformation zu Irbesartan und Hydrochlorothiazid, Warnhinweise und Vorsichtsmaßnahmen)

Concurrent use with potassium-containing medications, potassium-sparing diuretics and angiotensin-converting enzyme inhibitors (ACE inhibitors) may result in hyperkalemia and cardiac arrhythmias or cardiac arrest. (Fachinformation zu Kaliumiodid, Arzneimittelwechselwirkungen)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes [see Drug Interactions (7.1) ] . (Fachinformation zu Lisinopril, Warnhinweise und Vorsichtsmaßnahmen)

Use of lisinopril with potassium-sparing diuretics (e.g., spironolactone, eplerenone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. (Fachinformation zu Lisinopril und Hydrochlorothiazid, Arzneimittelwechselwirkungen)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Potassium Supplements and Potassium-Sparing Diuretics: Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. (Fachinformation zu Moexipril, Arzneimittelwechselwirkungen)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes [see Drug Interactions (7.3) ] . (Fachinformation zu Olmesartan, Warnhinweise und Vorsichtsmaßnahmen)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus and the concomitant use of agents such as potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes [see Drug Interactions (7.2) ] . (Fachinformation zu Perindopril, Warnhinweise und Vorsichtsmaßnahmen)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Potassium-Sparing Diuretics As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium [see Warnings and Precautions (5.5)] . (Fachinformation zu Sacubitril und Valsartan, Arzneimittelwechselwirkungen)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

This risk is increased by impaired renal function or concomitant potassium supplementation, potassium-containing salt substitutes or drugs that increase potassium, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers [see Drug Interactions ( 7.1 )] . (Fachinformation zu Spironolacton, Warnhinweise und Vorsichtsmaßnahmen)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Hyperkalemia Hyperkalemia may occur in patients on ARBs, particularly in patients with advanced renal impairment, heart failure, on renal replacement therapy, or on potassium supplements, potassium-sparing diuretics, potassium-containing salt substitutes or other drugs that increase potassium levels. (Fachinformation zu Telmisartan, Warnhinweise und Vorsichtsmaßnahmen)

Hyperkalemia Telmisartan Hyperkalemia may occur in patients on ARBs, particularly in patients with advanced renal impairment, heart failure, on renal replacement therapy, or on potassium supplements, potassium-sparing diuretics, potassium-containing salt substitutes or other drugs that increase potassium levels. (Fachinformation zu Telmisartan und Amlodipin, Warnhinweise und Vorsichtsmaßnahmen)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Use of potassium-sparing diuretics (spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes concomitantly with ACE inhibitors can increase the risk of hyperkalemia. (Fachinformation zu Trandolapril, Arzneimittelwechselwirkungen)

Potassium-sparing diuretics, potassium supplements or salt substitutes may lead to increases in serum potassium, and in heart failure patients, increases in serum creatinine ( 7.1 ) (Fachinformation zu Valsartan, Arzneimittelwechselwirkungen)

…Serum Potassium: Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart… (Fachinformation zu Valsartan und Hydrochlorothiazid, Arzneimittelwechselwirkungen)

Nonsteroidal Anti-inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Nonsteroidal Anti-inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Supplemental potassium and/or spironolactone may prevent hypokalemia and metabolic alkalosis in these patients. (Fachinformation zu Bumetanid, Warnhinweise)

Nonsteroidal Anti-inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Nonsteroidal Anti-inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Drug Interactions There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen. (Fachinformation zu Dobutamin, Arzneimittelwechselwirkungen)

Nonsteroidal Anti-inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Drug interactions may occur when anticholinergics are used with the following medications: antacids, antidiarrheals (adsorbent), other anticholinergics, antimyasthenics, cyclopropane, haloperidol, ketoconazole, metoclopramide, opioid (narcotic) analgesics, and potassium chloride. (Fachinformation zu Hyoscyamin, Arzneimittelwechselwirkungen)

Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Nonsteroidal Anti-inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

…been observed in limited experience with patients in whom milrinone was used concurrently with the following drugs: digitalis glycosides; lidocaine, quinidine; hydralazine, prazosin; isosorbide dinitrate, nitroglycerin; chlorthalidone, furosemide, hydrochlorothiazide, spironolactone; captopril; heparin, warfarin, diazepam, insulin; and potassium supplements. (Fachinformation zu Milrinon, Arzneimittelwechselwirkungen)

Nonsteroidal Anti-inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Nonsteroidal Anti-inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)